The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD

Transplant Immunology

Volumn 8, Issue 2, 2000, Pages 115-124

  Nikolova, Zariana ^a   Hof, Akiko ^a   Baumlin, Yves ^a   Hof, Robert P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Heterotopic cardiac grafting; Immunomodulator; Peripheral lymphocyte count

Indexed keywords

EVEROLIMUS; FINGOLIMOD; IMMUNOMODULATING AGENT;

ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ANIMALS; BODY WEIGHT; DRUG THERAPY, COMBINATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MALE; MYOCARDIUM; PROPYLENE GLYCOLS; RATS; RATS, INBRED LEW; SIROLIMUS; SPHINGOSINE; TRANSPLANTATION, HETEROTOPIC;

EID: 0033828090     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(00)00016-2     Document Type: Article

References (52)

1. Experimental graft arteriosclerosis. I. The Lewis-to-F344 allograft model
2. Chronic cardiac rejection in the Lew to F344 rat model
3. Synthetic MHC Class I peptide prolongs cardiac survival and attenuates transplant arteriosclerosis in the Lewis to Fischer 344 model of chronic allograft rejection
4. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allograft
5. Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts
6. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation
7. Effects of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats
8. Immunosuppressive action of FTY720 for a renal allograft rat model
9. Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model
10. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo
11. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons
12. FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A
13. FTY720, a novel immuno-suppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effects in combination with cyclosporine in rats
14. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotropic cardiac allografts and synergistic effects in combination with cyclosporine A
15. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine
16. Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival
17. Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus
18. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase
19. Inhibition of CTL induction by rapamycin. Il-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity
20. A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisolone-treated renal transplant recipients
21. Combined immunosuppression with cyclosporine (neoral) and SDZ-RAD in non-human primate lung transplantation: Systematic pharmaco-kinetic-based trials to improve efficacy and tolerability
22. SDZ RAD, a new rapamycin derivative. Synergism with cyclosporine
23. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation
24. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model
25. Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients
26. Effects of rapamycin analogue SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model
27. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation
28. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat
29. The mechanism of un-responsiveness to allografts induced by rapamycin and rapamycin/cyclosporine treatment in rats
30. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
31. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection
32. The effect of rapamycin on kidney function in the Sprague-Dawley rat
33. Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat
34. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model
35. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model
36. Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongreal canine model
37. Rapamycin: Immunosuppression, hypo-responsiveness, and side effects in a porcine renal allograft model
38. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy
39. Rapamycin in experimental renal allografts in primates
40. Rapamycin: Personal algorithms for use based on 250 treated renal allograft recipients
41. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice
42. FTY720: A novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing
43. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing
44. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation
45. Improved technique of heart transplantation in the rat
46. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group
47. FTY720: A new immunosuppressive agent with novel mechanism(s) of action
48. SDZ RAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo
49. Towards understanding the pathophysiology of chronic rejection
50. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation
51. Prevention of graft vessel disease by combined FTY720/cyclosporine A treatment in a rat carotid artery transplantation model
52. SDZ RAD inhibits cold ischemia-induced vascular remodeling